Abstract：
OBJECTIVE: Magnetic resonance-guided focused ultrasound (MRgFUS) is a novel noninvasive interventional technique for osteoid osteoma (OO). The purpose of this study was to evaluate the efficacy and safety of MRgFUS in the treatment of OO through a systematic review and meta-analysis of pain scores and post-treatment adverse events before and after MRgFUS treatment.
METHODS: A comprehensive literature search of PubMed, Embase, Web of science, and Cochrane Library databases was conducted to screen the study literature based on inclusion and exclusion criteria to extract and analyze pre- and post-treatment pain score data, success rates (complete pain relief with no recurrence until the last follow-up), recurrence rates, secondary intervention rates, and complications to evaluate the efficacy and/or safety of MRgFUS for OO.
RESULTS: A total of 113 studies published between 2012 and 2022were collected, resulting in a total sample size of 353 patients. The majority of the studies were prospective and had a follow-up period of 4 weeks or more, and overall, the quality of evidence ranged from low to high. Pain scores at 1 week and 1 month after the merger were 0.62 (9.5% CI:0.28-0.96) and 0.37 (9.5% CI:0.07-0.68), respectively. The success rate of the combination was 92.8% (95% CI: 89.8%-95.7%), the incidence of minor complications (thermal injury at the ablation site) was 0.85%, and no major complications were recorded in any of the included literature.
CONCLUSIONS: MRgFUS is an effective procedure that is able to treat pain for patients with OO with satisfying efficacy and safety.
UNASSIGNED: No.CRD42023415573.
METHODS: A comprehensive literature search of PubMed, Embase, Web of science, and Cochrane Library databases was conducted to screen the study literature based on inclusion and exclusion criteria to extract and analyze pre- and post-treatment pain score data, success rates (complete pain relief with no recurrence until the last follow-up), recurrence rates, secondary intervention rates, and complications to evaluate the efficacy and/or safety of MRgFUS for OO.
RESULTS: A total of 113 studies published between 2012 and 2022were collected, resulting in a total sample size of 353 patients. The majority of the studies were prospective and had a follow-up period of 4 weeks or more, and overall, the quality of evidence ranged from low to high. Pain scores at 1 week and 1 month after the merger were 0.62 (9.5% CI:0.28-0.96) and 0.37 (9.5% CI:0.07-0.68), respectively. The success rate of the combination was 92.8% (95% CI: 89.8%-95.7%), the incidence of minor complications (thermal injury at the ablation site) was 0.85%, and no major complications were recorded in any of the included literature.
CONCLUSIONS: MRgFUS is an effective procedure that is able to treat pain for patients with OO with satisfying efficacy and safety.
UNASSIGNED: No.CRD42023415573.
摘要：
目的：磁共振引导聚焦超声（MRgFUS）是一种新型的非侵入性骨样骨瘤（OO）介入技术。这项研究的目的是通过对MRgFUS治疗前后疼痛评分和治疗后不良事件的系统评价和荟萃分析，评估MRgFUS治疗OO的有效性和安全性。
方法：对PubMed，Embase,WebofScience,和CochraneLibrary数据库进行筛选，根据纳入和排除标准筛选研究文献，以提取和分析治疗前后的疼痛评分数据，成功率（完全缓解疼痛，直到最后一次随访才复发），复发率,二级干预率，和并发症，以评估MRgFUS用于OO的疗效和/或安全性。
结果：共收集了2012年至2022年间发表的113项研究，导致总样本量为353名患者。大多数研究是前瞻性的，随访时间为4周或更长时间，总的来说,证据质量从低到高不等。合并后1周和1个月疼痛评分分别为0.62(9.5%CI:0.28-0.96)和0.37(9.5%CI:0.07-0.68),分别。组合的成功率为92.8％（95％CI：89.8％-95.7％），轻微并发症（消融部位热损伤）的发生率为0.85％，纳入的任何文献均未记录到重大并发症.
结论：MRgFUS是一种有效的方法，能够治疗OO患者的疼痛，具有令人满意的疗效和安全性。
■编号.CRD42023415573。
方法：对PubMed，Embase,WebofScience,和CochraneLibrary数据库进行筛选，根据纳入和排除标准筛选研究文献，以提取和分析治疗前后的疼痛评分数据，成功率（完全缓解疼痛，直到最后一次随访才复发），复发率,二级干预率，和并发症，以评估MRgFUS用于OO的疗效和/或安全性。
结果：共收集了2012年至2022年间发表的113项研究，导致总样本量为353名患者。大多数研究是前瞻性的，随访时间为4周或更长时间，总的来说,证据质量从低到高不等。合并后1周和1个月疼痛评分分别为0.62(9.5%CI:0.28-0.96)和0.37(9.5%CI:0.07-0.68),分别。组合的成功率为92.8％（95％CI：89.8％-95.7％），轻微并发症（消融部位热损伤）的发生率为0.85％，纳入的任何文献均未记录到重大并发症.
结论：MRgFUS是一种有效的方法，能够治疗OO患者的疼痛，具有令人满意的疗效和安全性。
■编号.CRD42023415573。
